Expect near-term downward pressure on NBTX shares as the market absorbs the dilutive offering. Monitor pricing announcement on May 21 for exact terms and discount. The lock-up may limit insider selling but does not prevent post-offering volatility.
Price Chart
Executive Summary
Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-funded warrants. The offering is dilutive to existing shareholders (no preemptive rights) and priced at up to 15% discount to VWAP. Proceeds will fund pipeline (Nanoprimer, JNJ-1900/NBTXR3) and general corporate purposes. The dilutive capital raise weighs on near-term sentiment.
Key Financial Metrics
Key Facts
- ~€75M (~$87M) global follow-on offering of ADSs, ordinary shares, and pre-funded warrants
- Pricing at up to 15% discount to volume-weighted average price over last 3 sessions; underwriters have 30-day option for additional 15%
- Issued without preferential subscription rights, diluting existing shareholders
- Proceeds: <10% for JNJ-1900 (NBTXR3), 50-60% for Nanoprimer/other platforms, 30-40% for general corporate purposes
- 90-day lock-up for executives and board members; company also subject to lock-up
- Offering expected to price before US markets open on May 21, 2026; Euronext trading will be suspended on pricing day until Nasdaq opens
Financial Impact
~€75M (~$87M) capital raise; dilution of ~4% at current market cap before potential discount and greenshoe
Risk Factors
- Dilution to existing shareholders without preemptive rights
- Potential for larger offering if demand is high (greenshoe up to 15%)
- Uncertainty about final pricing and discount
- Execution risk in advancing Nanoprimer and NBTXR3 pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298950 |
| PRESS-RELEASE Data (Synthetic) | press-3298951 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 5d ago | 6-K | $25.83 | awaiting T+20 | — | $31.55 (+22.14%) |
Oct 1, 2026 24d ago | 6-K | $25.75 | awaiting T+20 | — | $31.55 (+22.52%) |
Oct 1, 2026 24d ago | Press Release | $25.75 | awaiting T+20 | — | $31.55 (+22.52%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.55 (+5.28%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.55 (−5.28%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.55 (−5.28%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.55 (−10.47%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.55 (−11.70%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.55 (−18.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers